Cemdisiran

Regeneron announced Phase 3 trial results showing the pozelimab and cemdisiran combination (poze-cemdi) outperformed ravulizumab in controlling intravascular hemolysis in PNH patients, with better LDH level management. A registrational cohort continues to explore poze-cemdi's efficacy against eculizumab.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH, with 96% achieving LDH control vs. 80% on ravulizumab. A registrational cohort is ongoing, comparing poze-cemdi to eculizumab. Poze-cemdi offers potential for self-administration with infrequent dosing.

Phase 3 trial data shows poze-cemdi, a first-in-class combination treatment, outperforms standard ravulizumab in controlling PNH disease, measured by LDH levels. Poze-cemdi achieved higher LDH control and normalization rates, with a safety profile consistent with approved C5 inhibitors. Ongoing studies aim to confirm these findings.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH, with better LDH levels. A registrational cohort is ongoing, comparing poze-cemdi to eculizumab. Poze-cemdi offers potential for self-administration and improved disease control.

Phase 3 trial data showed the poze-cemdi combination treatment achieved better disease control in PNH patients, measured by LDH levels, compared to standard ravulizumab. Poze-cemdi, combining an antibody and siRNA targeting C5, demonstrated superior LDH control and normalization, with potential for self-administration, indicating a promising treatment approach for PNH and other complement-mediated diseases.

Phase 3 trial data showed poze-cemdi combo treatment improved LDH control in PNH patients compared to ravulizumab, with 96% achieving adequate LDH control and 93% achieving normalization. A registrational cohort is ongoing, comparing poze-cemdi against eculizumab.

This press release contains forward-looking statements about Regeneron Pharmaceuticals' future performance, involving risks and uncertainties. It discusses potential regulatory approvals, market acceptance, and commercial success of its products and candidates, including pozelimab and cemdisiran for treating complement-mediated diseases. Risks include manufacturing, safety, regulatory judgments, competition, and the impact of public health crises like COVID-19.

Pozelimab and cemdisiran combination shows superior inhibition of terminal complement in PNH patients, achieving higher LDH control and normalization rates compared to ravulizumab, with potential for self-administration.

Regeneron Pharmaceuticals announced new data from its hematology pipeline at the ASH 2024 Annual Meeting, showcasing advancements in treating blood cancers and disorders. Key highlights include head-to-head results for pozelimab plus cemdisiran vs. ravulizumab in PNH, odronextamab's potential in follicular lymphoma, and progress in DLBCL and MZL treatments.